NeuroVision Imaging LLC (NeuroVision) provides digital imaging and diagnostic solutions for Alzheimer’s disease and eye care markets. The company develops a novel retinal imaging technology for offering diagnostic tests and biomarkers for the monitoring and detection of amyloid pathology related to Alzheimer’s disease. It provides biostatistics, analysis, data aggregation services and applications of machine learning algorithms to repositories of images and biomarker data for neurodegenerative diseases. NeuroVision is headquartered in Sacramento, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company NeuroVision Imaging LLC
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
NeuroVision Imaging LLC Company Overview
NeuroVision Imaging LLC Company Snapshot
NeuroVision Imaging LLC Pipeline Products and Ongoing Clinical Trials Overview
Blood-Based Screening Test - Alzheimer's Disease Product Overview
Blood-Based Screening Test - Dementia
Blood-Based Screening Test - Dementia Product Overview
Blood-Based Screening Test - Neurodegenerative Disorders
Blood-Based Screening Test - Neurodegenerative Disorders Product Overview
NeuroVision Imaging LLC - Key Employees
NeuroVision Imaging LLC - Locations And Subsidiaries
Head Office
Recent Developments
NeuroVision Imaging LLC, Recent Developments
Aug 24, 2021: NeuroVision Imaging announces additional funding from the ADDF to accelerate development of novel blood-based lab test to predict dementia before clinical onset
Feb 02, 2021: NeuroVision Imaging announces new funding from the ADDF to develop affordable, accessible biomarkers to diagnose Alzheimer’s and related dementias
Jul 18, 2018: NeuroVision Imaging appoints Dr. Roy Twyman as board directore
Aug 22, 2017: Clinical study shows that retinal imaging may detect signs of Alzheimer’s disease
Jun 29, 2016: NeuroVision announces participation in landmark Alzheimer’s A4 study evaluating its novel retinal imaging technology